Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lapatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 18/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 17/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.99 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.86 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.86 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.86 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.86 |
| ▸ | STK10 | O94804 | 1/20 | 0.86 |
| ▸ | ABL1 | P00519 | 1/20 | 0.86 |
| ▸ | INSR | P06213 | 1/20 | 0.86 |
| ▸ | RET | P07949 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.86 |
| ▸ | SRC | P12931 | 1/20 | 0.86 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.86 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.86 |
| ▸ | CDK2 | P24941 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lapatinib SCHEMBL571898 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL29356338 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL30680457 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL4097293 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL4926017 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL93590 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL29866632 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL31732815 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL1374543 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL1651711 | 0.95 | EGFR (0.91) | EGFRERBB2ABCB11MEN1PIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988462-B2 | Material and methods for treating or preventing HER-3 associated diseases | DAIICHI SANKYO EUROPE GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| US-9803025-B2 | Material and methods for treating or preventing HER-3 associated diseases | AMGEN, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160222126-A1 | MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES | U3 PHARMA GMBH (DE) | 2016-08-04 | — | — | US | disclosed |
| US-20140017166-A1 | MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES | AMGEN, INC. (US) | 2014-01-16 | — | — | US | disclosed |